Table 1. Selected hot-spot mutations in the HBV polymerase conferring drug resistance.
| HBV reverse transcriptase mutations | Nucleoside analogues | Nucleotide analogues | ||||
|---|---|---|---|---|---|---|
| LMV | LdT | ETV | ADV | TDF | ||
| Wildtype | S | S | S | S | S | |
| M204I | R | R | S | S | S | |
| L180M + M204V/S | R | R | I | S | S | |
| L180M + M204V/I ± T184G ± S202I/G | R | R | R | S | S | |
| L180M + M204V/I ± I169T ± V173L ± M250V | R | R | R | S | S | |
| A181T/V | I | S | S | R | S | |
| N236T | S | S | S | R | I | |
| A194T | R | S | S | ? | I | |
The susceptibility to the different drugs is indicated by sensitive (S), resistant (R) and intermediate/in vitro resistance (I). LMV, lamivudine; LdT, telbivudine; ETV, entecavir; ADV, adefovir dipivoxil; TDF, tenofovir; HBV, hepatitis B virus.